A型肉毒素注射治疗糖尿病膀胱尿道功能障碍的临床研究  

Clinical research of urethra function disorders in diabetic bladder by injecting botulinum toxin type-A

作　　者：马小荣[1] 杨言春[1] 白大春[1] 李亚坤[1] 胡文启[1] 景建斌[1] 

机构地区：[1]兰州市第二人民医院泌尿外科,甘肃兰州730046

出　　处：《甘肃医药》2013年第2期97-100,共4页Gansu Medical Journal

摘　　要：目的:通过对经尿道镜于尿道外括约肌注射A型肉毒毒素(BTX-A)治疗糖尿病膀胱尿道功能障碍病例的临床疗效的观察,寻求此类病例的最佳治疗方法。方法:在我院就诊的糖尿病膀胱尿道功能障碍患者30例。经尿道镜于尿道外括约肌多点注射A型肉毒毒素(BTX-A)进行治疗。对治疗前后患者症状及各项尿动力参数变化进行观察比较。结果:30例糖尿病并发膀胱尿道功能障碍患者经尿道镜尿道外括约肌注射A型肉毒毒素(BTX-A)后3～7d起效,平均5.8d。患者随访2～8个月,28例效果明显,2例患者治疗后效果减退,准备行第2次注射。结论:A型肉毒毒素(BTX-A)经尿道镜尿道外括约肌注射治疗糖尿病膀胱尿道功能障碍,患者症状改善明显,各项客观指标更趋正常,操作简单,治疗效果确切,无毒副作用。Objective：To search for the best approach in current through transurethral injecting botulinum toxin type-A into urethral sphincter for treatment of urethra function disorders in diabetic bladder. Methods： 30 cases of urethra function disorders in diabetic bladder were injected botulinum toxin type-A into urethral sphincter by transurethral multi-point in which patient＇s symptoms and urodynamic parameter changes in preprocedure and postprocedure were observed and compared. Results： Onset time of positive effect was 3-7d after injection of type A botulinum toxin （BTX-A）, an average of 5.8d. The patient were followed up for 2-8 months in which 28 cases were effective ,2 patients were diminished after treatment who needed undertaken the second injection. Conclusion： Transurethral injection of botulinum toxin type-A into urethral sphincter is still in the developmental stages and their roles in the management of incontinence still need to be defined more precisely. Because the method are less invasive and generally performed on an outpatient basis,medical costs should be reduced, and there should also be a more rapid retum to the patient＇s normal activities.

关 键 词：A型肉毒毒素 糖尿病 膀胱尿道功能障碍 

分 类 号：R699[医药卫生—泌尿科学]